Examples of using Presented in order of decreasing seriousness in English and their translations into Slovenian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
Within each frequency grouping, ADRs are presented in order of decreasing seriousness.
Adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common(≥ 1/10), common(≥ 1/100 to< 1/10).
Within each frequency category, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common(≥ 1/10), common(≥ 1/100 to< 1/10), uncommon(≥ 1/1000 to< 1/100) and not known(cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common> 1/ 10, common> 1/ 100,< 1/10, uncommon> 1/ 1000,< 1/ 100.
Within each frequency grouping and systemorgan class, adverse reactions are presented in order of decreasing seriousness.
Each term is presented in its most common category only and withineach frequency grouping, adverse reactions are presented in order of decreasing seriousness.
The following ADRs were reported during clinical trials with GANFORT(within each frequency grouping,undesirable effects are presented in order of decreasing seriousness).
Within each frequency grouping, adverse events are presented in order of decreasing seriousness.
Table 1 presents the adverse reactions that have been reported during clinical studies with GANFORT(within each frequency grouping,adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1 presents the adverse reactions that were reported during a 12-week clinical study of GANFORT single-dose(within each frequency grouping,adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1 presents the adverse reactions that have been reported during clinical studies with all GANFORT formulations(multi-dose and single-dose)(within each frequencygrouping, adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.
Within each frequency category, the adverse reactions are presented in order of decreasing seriousness.
Table 1 presents the adverse reactions that were reported during clinical studies of both GANFORT single-dose and Ganfort multi-dose formulations(within eachfrequency grouping, adverse reactions are presented in order of decreasing seriousness) or in the post-marketing period.
Within each frequency grouping,adverse reactions have been presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Within each system organ class, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Within each frequency grouping adverse reactions are presented in order of decreased seriousness.